Cyclo Therapeutics, Inc.

NasdaqCM:CYTH Voorraadrapport

Marktkapitalisatie: US$20.7m

Cyclo Therapeutics Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Cyclo Therapeutics's earnings have been declining at an average annual rate of -23.3%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 4.1% per year.

Belangrijke informatie

-23.3%

Groei van de winst

39.7%

Groei van de winst per aandeel

Biotechs Groei van de industrie17.0%
Inkomstengroei4.1%
Rendement op eigen vermogenn/a
Nettomarge-1,831.3%
Laatste winstupdate30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

Cyclo Therapeutics GAAP EPS of -$0.41 beats by $0.12, revenue of $0.54M misses by $0.08M

Aug 16

Here's Why We're A Bit Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Situation

Jul 12
Here's Why We're A Bit Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Situation

We're A Little Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate

Jan 20
We're A Little Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate

Cyclo Therapeutics: Addressing The Fundamentals Of Alzheimer's Disease

Nov 16

Will Cyclo Therapeutics (NASDAQ:CYTH) Spend Its Cash Wisely?

Sep 28
Will Cyclo Therapeutics (NASDAQ:CYTH) Spend Its Cash Wisely?

Cyclo therapeutics to join Russell 2000 Index

Jun 14

We're Keeping An Eye On Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate

Jun 12
We're Keeping An Eye On Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate

Cyclo Therapeutics posts design protocol of pivotal late-stage study of Trappsol Cyclo

Apr 27

Opbrengsten en kosten

Hoe Cyclo Therapeutics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

NasdaqCM:CYTH Opbrengsten, kosten en inkomsten (USD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 241-21814
31 Mar 241-19814
31 Dec 231-20714
30 Sep 231-19713
30 Jun 231-19713
31 Mar 231-18811
31 Dec 221-1589
30 Sep 222-1387
30 Jun 222-1386
31 Mar 221-1377
31 Dec 212-1479
30 Sep 211-1469
30 Jun 211-1248
31 Mar 211-1047
31 Dec 201-946
30 Sep 201-937
30 Jun 201-937
31 Mar 201-846
31 Dec 191-835
30 Sep 191-634
30 Jun 191-534
31 Mar 191-534
31 Dec 181-423
30 Sep 181-433
30 Jun 181-432
31 Mar 181-432
31 Dec 171-432
30 Sep 172-322
30 Jun 172-432
31 Mar 171-532
31 Dec 162-432
30 Sep 161-432
30 Jun 161-431
31 Mar 161-321
31 Dec 151-321
30 Sep 151-220
30 Jun 151-120
31 Mar 151-120
31 Dec 142-120
30 Sep 141010
30 Jun 141010
31 Mar 142010
31 Dec 132010

Kwaliteitswinsten: CYTH is currently unprofitable.

Groeiende winstmarge: CYTH is currently unprofitable.


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: CYTH is unprofitable, and losses have increased over the past 5 years at a rate of 23.3% per year.

Versnelling van de groei: Unable to compare CYTH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Winst versus industrie: CYTH is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Rendement op eigen vermogen

Hoge ROE: CYTH's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden